iti-214
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01900522)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12- Mol. weight
- 507.57 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3769414 ↗
Also known as
- iti-214
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05766813 | Phase 2 | Mar 13, 2023 | Intra-Cellular Therapies |
| NCT03387215 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2018 | Intra-Cellular Therapies |
| NCT03489772 | Phase 1 | Jul 10, 2018 | Intra-Cellular Therapies, Laureate Institute for Brain Research |
| NCT03257046 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2017 | Intra-Cellular Therapies |
| NCT01900522 | Phase 1 | Jul 1, 2013 | Intra-Cellular Therapies, Takeda |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intra-Cellular Therapies | For profit | 5 | 4 | 2 | 2013 |
| Laureate Institute for Brain Research | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Takeda | For profit | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1